Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Herbal Medicine Market

ID: MRFR/HC/11126-HCR
128 Pages
Satyendra Maurya
Last Updated: May 04, 2026

US Herbal Medicine Market Research Report By Herbal Medicine Form Outlook (Extracts, Powders, Capsules Tablets, Syrups), By Herbal Medicine Distribution Channel Outlook (Hospital Retail Pharmacies, E-Commerce), By Herbal Medicine Category Outlook (Herbal Pharmaceuticals, Herbal Functional Foods, Herbal Beauty Products, Herbal Dietary Supplements), By Herbal Medicine Type of Medicinal Plants (Marrubium Vulgare, Vaccinium Macrocarpon, Echinacea, Curcuma Longa, Camellia Sinensis, Actaea Racemose, Aloe Vera, Zingiber Officinale, Cocos Nucifera, Cinnamomum Spp, Allium Sativum) and By Herbal Medicine Source Outlook (Leaves, Root Barks, Whole Plants, Fruits) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Herbal Medicine Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Pharmaceutical, BY Form (USD Billion) | |
      1. 4.1.1 Extracts | |
      2. 4.1.2 Powders | |
      3. 4.1.3 Capsules & Tablets | |
      4. 4.1.4 Syrups |
    2. 4.2 Pharmaceutical, BY Distribution Channel (USD Billion) | |
      1. 4.2.1 Hospital & Retail Pharmacies | |
      2. 4.2.2 E-Commerce |
    3. 4.3 Pharmaceutical, BY Category (USD Billion) | |
      1. 4.3.1 Herbal Pharmaceuticals | |
      2. 4.3.2 Herbal Functional Foods | |
      3. 4.3.3 Herbal Beauty Products | |
      4. 4.3.4 Herbal Dietary Supplements |
    4. 4.4 Pharmaceutical, BY Type of Medicinal Plants (USD Billion) | |
      1. 4.4.1 Marrubium Vulgare | |
      2. 4.4.2 Vaccinium Macrocarpon | |
      3. 4.4.3 Echinacea | |
      4. 4.4.4 Curcuma Longa | |
      5. 4.4.5 Camellia Sinensis | |
      6. 4.4.6 Actaea Racemose | |
      7. 4.4.7 Aloe Vera | |
      8. 4.4.8 Zingiber Officinale | |
      9. 4.4.9 Cocos Nucifera | |
      10. 4.4.10 Cinnamomum Spp | |
      11. 4.4.11 Allium Sativum |
    5. 4.5 Pharmaceutical, BY Source (USD Billion) | |
      1. 4.5.1 Leaves | |
      2. 4.5.2 Root & Barks | |
      3. 4.5.3 Whole Plants | |
      4. 4.5.4 Fruits 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Herbalife (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Nature's Way (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Gaia Herbs (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Traditional Medicinals (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Schwabe Pharmaceuticals (DE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Dabur (IN) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Himalaya Wellness (IN) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Zandu Pharmaceutical Works (IN) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 US MARKET ANALYSIS BY FORM |
    6. 6.3 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    7. 6.4 US MARKET ANALYSIS BY CATEGORY |
    8. 6.5 US MARKET ANALYSIS BY TYPE OF MEDICINAL PLANTS |
    9. 6.6 US MARKET ANALYSIS BY SOURCE |
    10. 6.7 KEY BUYING CRITERIA OF PHARMACEUTICAL |
    11. 6.8 RESEARCH PROCESS OF MRFR |
    12. 6.9 DRO ANALYSIS OF PHARMACEUTICAL |
    13. 6.10 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL |
    14. 6.11 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL |
    15. 6.12 SUPPLY / VALUE CHAIN: PHARMACEUTICAL |
    16. 6.13 PHARMACEUTICAL, BY FORM, 2024 (% SHARE) |
    17. 6.14 PHARMACEUTICAL, BY FORM, 2024 TO 2035 (USD Billion) |
    18. 6.15 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    19. 6.16 PHARMACEUTICAL, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    20. 6.17 PHARMACEUTICAL, BY CATEGORY, 2024 (% SHARE) |
    21. 6.18 PHARMACEUTICAL, BY CATEGORY, 2024 TO 2035 (USD Billion) |
    22. 6.19 PHARMACEUTICAL, BY TYPE OF MEDICINAL PLANTS, 2024 (% SHARE) |
    23. 6.20 PHARMACEUTICAL, BY TYPE OF MEDICINAL PLANTS, 2024 TO 2035 (USD Billion) |
    24. 6.21 PHARMACEUTICAL, BY SOURCE, 2024 (% SHARE) |
    25. 6.22 PHARMACEUTICAL, BY SOURCE, 2024 TO 2035 (USD Billion) |
    26. 6.23 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    27. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    28. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY FORM, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY CATEGORY, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY TYPE OF MEDICINAL PLANTS, 2025-2035 (USD Billion) | |
      5. 7.2.5 BY SOURCE, 2025-2035 (USD Billion) |
    29. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.3.1 |
    30. 7.4 ACQUISITION/PARTNERSHIP | |

US Pharmaceutical Market Segmentation

Pharmaceutical By Form (USD Billion, 2025-2035)

  • Extracts
  • Powders
  • Capsules & Tablets
  • Syrups

Pharmaceutical By Distribution Channel (USD Billion, 2025-2035)

  • Hospital & Retail Pharmacies
  • E-Commerce

Pharmaceutical By Category (USD Billion, 2025-2035)

  • Herbal Pharmaceuticals
  • Herbal Functional Foods
  • Herbal Beauty Products
  • Herbal Dietary Supplements

Pharmaceutical By Type of Medicinal Plants (USD Billion, 2025-2035)

  • Marrubium Vulgare
  • Vaccinium Macrocarpon
  • Echinacea
  • Curcuma Longa
  • Camellia Sinensis
  • Actaea Racemose
  • Aloe Vera
  • Zingiber Officinale
  • Cocos Nucifera
  • Cinnamomum Spp
  • Allium Sativum

Pharmaceutical By Source (USD Billion, 2025-2035)

  • Leaves
  • Root & Barks
  • Whole Plants
  • Fruits

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓